Biochemistry, Physiology, Thermodynamics,  Nutrition News and Research

Why is semaglutide more popular than tirzepatide?

October 1, 2025 / 0 Comments

In just a few years, drugs like Ozempic, Wegovy, and Mounjaro have gone from niche diabetes treatments to household names. They’re not just controlling blood sugar anymore — they’re reshaping how we think about obesity, metabolism, and long-term health.

Among the most widely used are semaglutide and tirzepatide. Both are powerful tools in diabetes and weight management, but they work in slightly different ways — and those differences matter.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1). It mimics a natural hormone produced in the gut that:

  • Slows stomach emptying, keeping you fuller for longer.
  • Increases insulin release to control blood sugar.
  • Reduces cravings through effects on the brain.

Familiar brand names include Ozempic, Wegovy, and Rybelsus.

How Tirzepatide Works

Tirzepatide takes it one step further. It’s a dual agonist, targeting both GLP-1 and another hormone receptor, GIP (glucose-dependent insulinotropic polypeptide). By activating two receptors instead of one, tirzepatide can:

  • Boost insulin secretion more effectively.
  • Enhance appetite suppression.
  • Improve glucose metabolism beyond what semaglutide alone can achieve.

Its trade names are Mounjaro and Zepbound.

Head-to-Head: Which Works Better?

Clinical trials have compared the two drugs, and the results consistently favor tirzepatide:

  • More weight loss: Patients lose more pounds on tirzepatide than on semaglutide at similar doses.
  • Better glucose control: Blood sugar levels improve more on tirzepatide.
  • Cardiovascular benefits: In patients with heart disease, tirzepatide has been linked to fewer heart attacks, slower disease progression, and lower overall mortality.
  • Cost-effectiveness: One study estimated that weight loss with semaglutide costs about $1,845 per pound lost, while tirzepatide averaged $945 per pound.

Why Is Semaglutide Still More Prescribed?

Despite tirzepatide’s advantages, semaglutide remains more common. Two key reasons explain why:

  1. Longer track record: Semaglutide was FDA-approved in 2017, while tirzepatide only gained approval in 2022. Doctors and insurers are more comfortable with semaglutide’s established safety data.
  2. Insurance coverage: Some health plans cover semaglutide but not tirzepatide. Without insurance, both drugs cost $500–$1,500 per month, which puts them out of reach for many.

As of 2025, about 6% of Americans are currently taking a GLP-1 agonist (semaglutide or tirzepatide), and nearly 12% have tried one. The main reasons people stop? Side effects like nausea — and the price tag.

The Bottom Line

Both semaglutide and tirzepatide are transforming diabetes and obesity treatment. But when it comes to weight loss, blood sugar control, and heart health, tirzepatide appears to have the edge. The biggest question now is whether insurance, cost, and time will allow tirzepatide to catch up — and perhaps surpass — semaglutide as the most widely used option.

Summary

Semaglutide and tirzepatide are leading the charge in modern metabolic care. Both improve appetite control, glucose metabolism, and weight loss, but evidence suggests tirzepatide provides greater overall benefits. For now, semaglutide dominates prescriptions due to its longer approval history and wider insurance coverage — but tirzepatide is quickly rising, and it may soon reshape the treatment landscape.

References

  1. Moiz, Areesha et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine, Volume 138, Issue 6, 934 – 940. 10.1016/j.amjmed.2025.01.021
  2. Dani, S, Makwana, B, Khadke, S. et al. An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists. JACC Adv. 2025 May, 4 (5) . https://doi.org/10.1016/j.jacadv.2025.101740
  3. Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obes Metab. 2023; 25(4): 961-964. doi:10.1111/dom.14940
  4. Understanding the Differences Between Semaglutide and Tirzepatide, 2024 Jun, 10.